Antibody profiles for the diagnosis of antiphospholipid syndrome
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Summary: Among the so called‘antiphospholipid antibodies’, the presence of Lupus Anticoagulant (LA) is associated with thrombosis-related events and defines the antiphospholipid syndrome. The role of anti-cardiolipin (aCL) antibodies and anti-human β2-glycoprotein I (aβ2GPI) antibodies is less striking. Since the problem of standardization for these tests is far from resolved, we evaluated whether the combination of results (antiphospholipid laboratory profiles) could help to better classify these patients. Over a 6-year period, 618 consecutive subjects (55% of whom had previous documented thrombosis-related events) were referred to our clinic for Antiphospholipid antibody detection. LA was detected according to internationally accepted recommendations. ACL and aβ2GPI antibodies were detected by Enzyme-Linked-Immunosorbent Assay (ELISA). Patients’ records were reviewed for the presence of previous thromboembolic events or obstetric complications according to Sapporo’s clinical criteria for the diagnosis of antiphospholipid syndrome (APS) and each patient underwent a physical examination. When individual tests were considered in a multivariate analysis which took into account age, gender, the presence of SLE or other autoimmune diseases and established risk factors for venous and arterial thromboembolism, LA (Odds Ratio 4.4, Confidence Interval 1.5–13.3) and aβ2GPI antibodies (Odds Ratio 2.9, Confidence Interval 1.1–7.5) but not aCL antibodies (Odds Ratio 1.2, Confidence Interval 0.5–2.7) were found to be independent risk factors for thrombosis-related events. When antiphospholipid antibody profiles instead of individual test positivity were analyzed in the above mentioned model, triple positivity resulted a strong independent risk factor (Odds Ratio 33.3, Confidence Interval 7.0–157.6), retaining its significance when the association with venous or arterial thromboembolism was considered. Double positivity with negative LA was close to significance for thrombosis-related events (Odds Ratio 2.2, Confidence Interval1.0–5.2, p=0.056) and highly significant risk factor for obstetric complications (Odds Ratio 10.8, Confidence Interval 2.9–40.8). Other combinations did not reach statistical significance. The mean level of IgG aβ2GPI antibodies was statistically higher in triple positive profile and might account for positive LA. As compared to a single test, the analysis of a complete antiphospholipid antibody profile can better determine patients at risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
Galli, M., Barbui, T., Comfurius, P., Maassen, C., Hemker, H. C., Zwaal, R. F. A., Bevers, E. M., de Baets, M. H., & van Breda-Vriesman, P. J. C. (1990) · The Lancet · doi:10.1016/0140-6736(90)91374-j · Cited by 1,270
Brandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 972
Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease
Matsuura, E., Igarashi, Y., Fujimoto, M., Ichikawa, K., & Koike, T. (1990) · The Lancet · doi:10.1016/0140-6736(90)91697-9 · Cited by 720
Bevers, E. M., Galli, M., Barbui, T., Comfurius, P., & Zwaal, R. F. A. (1991) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646476 · Cited by 576
Matsuura, E., Igarashi, Y., Yasuda, T., Triplett, D. A., & Koike, T. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.2.457 · Cited by 529
Finazzi, G., Brancaccio, V., Moia, M., Ciavarella, N., Mazzucconi, M. G., Schinco, P., Ruggeri, M., Pogliani, E. M., Gamba, G., Rossi, E., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00060-5 · Cited by 427
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-11-3334 · Cited by 413
Roubey, R. A. S., Eisenberg, R. A., Harper, M. F., & Winfield, J. B. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.2.954 · Cited by 329
Cited by
Ruiz-Irastorza, G., Crowther, M., Branch, W., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 831
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Pengo, V., Denas, G., Zoppellaro, G., Jose, S. P., Hoxha, A., Ruffatti, A., Andreoli, L., Tincani, A., Cenci, C., Prisco, D., et al. (2018) · Blood · doi:10.1182/blood-2018-04-848333 · Cited by 822
Self-citationClinical course of high‐risk patients diagnosed with antiphospholipid syndrome
PENGO, V., RUFFATTI, A., LEGNANI, C., GRESELE, P., BARCELLONA, D., ERBA, N., TESTA, S., MARONGIU, F., BISON, E., DENAS, G., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03674.x · Cited by 632
Self-citationRuiz-Irastorza, G., Cuadrado, M., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V, et al. (2011) · Lupus · doi:10.1177/0961203310395803 · Cited by 506
Self-citationPengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., De Micheli, V., Gresele, P., Tonello, M., Ghirarduzzi, A., et al. (2011) · Blood · doi:10.1182/blood-2011-03-340232 · Cited by 468
Self-citationSchreiber, K., Sciascia, S., de Groot, P. G., Devreese, K., Jacobsen, S., Ruiz-Irastorza, G., Salmon, J. E., Shoenfeld, Y., Shovman, O., & Hunt, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.103 · Cited by 359
DE LAAT, B., PENGO, V., PABINGER, I., MUSIAL, J., VOSKUYL, A. E., BULTINK, I. E. M., RUFFATTI, A., ROZMAN, B., KVEDER, T., DE MOERLOOSE, P., et al. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03588.x · Cited by 291
Self-citationLaboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH
Devreese, K. M. J., Ortel, T. L., Pengo, V., & de Laat, B. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13976 · Cited by 269
Self-citationGalli, M., Borrelli, G., Jacobsen, E. M., Marfisi, R. M., Finazzi, G., Marchioli, R., Wisloff, F., Marziali, S., Morboeuf, O., & Barbui, T. (2007) · Blood · doi:10.1182/blood-2007-01-066043 · Cited by 170
“More recently, retrospective studies have found thrombosis to be associated with the presence of β2GPI-dependent LA activity (12) and with the combined positivity for LA, aCL and aβ2GPI antibodies (13).”
BackgroundAntibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity
Ruffatti, A., Tonello, M., Del Ross, T., Cavazzana, A., Grava, C., Noventa, F., Tona, F., Iliceto, S., & Pengo, V. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-05-0287 · Cited by 170
“From a laboratory point of view, triple positive women had high IgG aβ2GPI titres that may account for LA positivity and TE events (5, 7).”
BackgroundSelf-citationMustonen, P., Lehtonen, K. V., Javela, K., & Puurunen, M. (2014) · Lupus · doi:10.1177/0961203314545410 · Cited by 127
Pengo, V., Ruffatti, A., Tonello, M., Cuffaro, S., Banzato, A., Bison, E., Denas, G., & Padayattil Jose, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12865 · Cited by 126
Self-citationSCIASCIA, S., MURRU, V., SANNA, G., ROCCATELLO, D., KHAMASHTA, M. A., & BERTOLACCINI, M. L. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12014 · Cited by 116
Devreese, K. M. J., Bertolaccini, M. L., Branch, D. W., de Laat, B., Erkan, D., Favaloro, E. J., Pengo, V., Ortel, T. L., Wahl, D., & Cohen, H. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.10.022 · Cited by 110
Self-citationMale, C., Foulon, D., Hoogendoorn, H., Vegh, P., Silverman, E., David, M., & Mitchell, L. (2005) · Blood · doi:10.1182/blood-2005-05-2048 · Cited by 106
Pengo, V., Ruffatti, A., Del Ross, T., Tonello, M., Cuffaro, S., Hoxha, A., Banzato, A., Bison, E., Denas, G., Bracco, A., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12264 · Cited by 101
Self-citationAntiphospholipid antibody testing and standardization
Devreese, K. M. J. (2014) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12234 · Cited by 98
Chayoua, W., Kelchtermans, H., Gris, J., Moore, G. W., Musiał, J., Wahl, D., de Groot, P. G., de Laat, B., & Devreese, K. M. J. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14633 · Cited by 89
Sevim, E., Zisa, D., Andrade, D., Sciascia, S., Pengo, V., Tektonidou, M. G., Ugarte, A., Gerosa, M., Belmont, H. M., Zamorano, M. A. A., et al. (2022) · Arthritis Care & Research · doi:10.1002/acr.24468 · Cited by 88
Self-citationLaboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome
Devreese, K., & Hoylaerts, M. F. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01243.x · Cited by 78
Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances
Vandevelde, A., & Devreese, K. M. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082164 · Cited by 76
Chayoua, W., Kelchtermans, H., Moore, G. W., Musiał, J., Wahl, D., de Laat, B., & Devreese, K. M. J. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14261 · Cited by 71
Cattini, M. G., Bison, E., Pontara, E., Cheng, C., Denas, G., & Pengo, V. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14765 · Cited by 68
Self-citationCorrect laboratory approach to APS diagnosis and monitoring
Pengo, V., Banzato, A., Denas, G., Jose, S. P., Bison, E., Hoxha, A., & Ruffatti, A. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.11.008 · Cited by 62
“We have shown that triple aPL positivity, as defined by the presence of LA andhigh titers of aCL and aβ2-GPI antibodies, correlates betterwith both thrombosis and pregnancy morbidity than any other aPL profile [3,24].”
BackgroundResultSelf-citationAntiphospholipid antibodies: Evaluation of the thrombotic risk
Devreese, K. M. J. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.08.270 · Cited by 56
Vikerfors, A., Johansson, A.-B., Gustafsson, J. T., Jonsen, A., Leonard, D., Zickert, A., Nordmark, G., Sturfelt, G., Bengtsson, A., Ronnblom, L., et al. (2013) · Rheumatology · doi:10.1093/rheumatology/kes252 · Cited by 51
De Kesel, P. M., & Devreese, K. M. J. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14894 · Cited by 40
Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus
Demir, S., Li, J., Magder, L. S., & Petri, M. (2021) · Rheumatology · doi:10.1093/rheumatology/keaa857 · Cited by 39
Del Ross, T., Ruffatti, A., Cuffaro, S., Tonello, M., Calligaro, A., Favaro, M., Facchinetti, M., Hoxha, A., & Punzi, L. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.08.019 · Cited by 27
Bertin, D., Camoin‐Jau, L., Veit, V., Resseguier, N., Lambert, M., Buffet Delmas, P., Heim, X., Mège, J., Morange, P., & Bardin, N. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15518 · Cited by 21
The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome
da Silva Saraiva, S., de Moraes Mazetto, B., Quinteiro Tobaldine, L., Pereira Colella, M., Vinícius De Paula, E., Annichinno‐Bizzachi, J., & Andrade Orsi, F. (2017) · American Journal of Hematology · doi:10.1002/ajh.24875 · Cited by 18
The Diagnosis of the Antiphospholipid Syndrome
Pengo, V., Ruffatti, A., & Iliceto, S. (2006) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000093564 · Cited by 12
Self-citationLupus anticoagulant test persistence over time and its associations with future thrombotic events
Colling, M. E., Ay, C., Kraemmer, D., Koder, S., Quehenberger, P., Pabinger, I., Posch, F., & Gebhart, J. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006011 · Cited by 5
“Age at entry, years (IQR) 164 (0%) 41 (31-58)”
BackgroundAnti‐β2‐glycoprotein I antibody testing in the laboratory diagnosis of antiphospholipid syndrome
PENGO, V. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01444.x · Cited by 3
Self-citation
Metadata
- Authors
- Biasiolo, A., Pegoraro, C., Cucchini, U., Noventa, F., Iliceto, S., & Pengo, V.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2005
- Volume
- 93
- Issue
- 06
- Pages
- 1147-1152
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2041919675
- Cited by
- 320
- References
- 34
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.